drugset / Trial / NCT04412174
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
NaSingle-groupOpen-labelTreatment
Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-NHL. The investigators plan to include 18 subjects to receive GC022F therapy.
Timeline
- Start
- 2020-06
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC022F | Cell therapy | 300000 cells/kg | — |
| Subject | GC022F | Cell therapy | 1e+06 cells/kg | — |